Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Diane Weiser - VP, Corporate Affairs
Robert Blum - President, CEO
Fady Malik - EVP, R&D
Chris Murray - SVP, Regulatory Affairs and Quality
Andrew Callos - EVP and Chief Commercial Officer
Stuart Kupfer - SVP and Chief Medical Officer
Sung Lee - EVP and CFO
Conference Call Participants
Salim Syed - Mizuho
Akash Tewari - Jefferies
Roanna Ruiz - Leerink
Paul Choi - Goldman Sachs
Kripa Devarakonda - Truist Securities
Charles Duncan - Cantor
Jason Butler - Citizens JMP
Sean McCutcheon - Raymond James
John Gionco - Needham & Co.
Rohan Mathur - Oppenheimer
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Second Quarter 2024 Conference Call. At this time, I would like to inform you that this call is being recorded. And all participants are in a listen-only mode. At the company’s request, we will open the call to questions after the presentation [Operator Instructions].
I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Affairs. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments; Fady Malik, EVP of R&D, will provide updates related to SEQUOIA-HCM and the ongoing clinical trials program for aficamten; Chris Murray, SVP, Regulatory Affairs and Quality, will provide an update from our recent interactions with FDA and EMA and the progress of our planned regulatory filings; Andrew Callos, EVP and Chief Commercial Officer, will address commercial readiness activities for aficamten.
Stuart Kupfer, SVP and Chief Medical Officer, will provide updates regarding omecamtiv mecarbil, CK-586 and our earlier stage development pipeline; Sung Lee, EVP and Chief Financial Officer, will provide a financial overview of the second quarter and review our updated financial guidance for 2024. And finally, Robert Blum review our corporate development strategies and review expected upcoming milestones.
Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements.
Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our second quarter 2024 financial results filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call.